Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Keralac Nailstik is a topical keratolytic solution containing 50% urea, primarily used for the treatment of hyperkeratotic skin conditions and nail disorders. Developed by Pharmaderm (a division of Sandoz), the product functions as a potent humectant and keratolytic agent. Urea works by increasing the water-binding capacity of the stratum corneum and solubilizing or denaturing proteins such as keratin, which softens dry, thick, or damaged skin and nail tissue. This process facilitates the shedding of dead skin cells and the non-surgical debridement or removal of devitalized or dystrophic nails. It is indicated for conditions including psoriasis, eczema, xerosis, ichthyosis, and corns, and is typically applied twice daily to the affected areas using a specialized applicator.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Keralac Nailstik.